Italy's premier orthopaedic research hospital specializing in bone regeneration, rare skeletal diseases, and translational clinical trials for advanced musculoskeletal therapies.
Istituto Ortopedico Rizzoli is one of Italy's leading orthopaedic research hospitals, based in Bologna, specializing in musculoskeletal diseases, bone regeneration, and skeletal rare disorders. They conduct clinical trials on advanced therapies — from mesenchymal stem cell treatments for joint degeneration to drug repurposing for skeletal dysplasia — and contribute clinical expertise and patient cohorts to large European research consortia. Their work spans the full translational pipeline: preclinical biomaterial development, in-silico and in-vitro modelling, and multicentre clinical validation, with a strong emphasis on orthopaedic precision medicine and rare bone diseases.
Core contributor across ADIPOA2 (stem cell therapy for osteoarthritis), ORTHOUNION (bone marrow MSC for fracture non-union), ADMAIORA (nanocomposite materials for osteoarthritis), and PREMUROSA (musculoskeletal regeneration and 3D bioprinting).
Active in MCDS-Therapy (skeletal dysplasia drug repurposing), EJP RD (European rare disease programme), SELNET (rare sarcoma tumours), and ERICA (rare disease research coordination).
Contributes to ITCC-P4 (paediatric preclinical platform with organoid and PDX models) and VAGABOND (actionable genomic aberrations in paediatric cancers).
Clinical partner in FURTHER (focused ultrasound for bone metastasis pain palliation) and ADMAIORA (ultrasound-mediated osteoarthritis management).
Participated in ADOPT BBMRI-ERIC (biobank gateway), CORBEL (life-science research infrastructures), and EJP RD (FAIR data sharing for rare diseases).
In their early H2020 period (2015–2017), IOR focused on foundational biomedical infrastructure — biobanking (ADOPT BBMRI-ERIC, CORBEL), stem cell clinical trials (ADIPOA2), and prosthetics (DeTOP) — building capacity across a broad range of orthopaedic and biomedical topics. From 2019 onward, their focus sharpened toward clinical translation in two clear directions: rare musculoskeletal diseases (EJP RD, ERICA, SELNET) and advanced therapeutic technologies like MR-guided focused ultrasound (FURTHER) and precision medicine with 3D bioprinting (PREMUROSA, ADMAIORA). The shift shows a maturing institution moving from infrastructure participation toward disease-specific clinical innovation and health economics evaluation.
IOR is converging on precision orthopaedic medicine — combining advanced therapeutics (focused ultrasound, bioprinting, nanocomposites) with rare disease expertise and health economics assessment, positioning them for translational clinical trials.
IOR operates exclusively as a clinical and research partner — never as coordinator across all 15 H2020 projects, with 3 additional involvements as a third party. They consistently join large, multinational consortia (300 unique partners across 43 countries), contributing specialist orthopaedic clinical expertise, patient access, and validation capacity rather than leading project design. This makes them a reliable, low-friction partner who brings deep clinical domain knowledge without competing for project leadership.
IOR has collaborated with 300 unique partners across 43 countries, making them exceptionally well-connected for a specialist orthopaedic institute. Their network spans all of Europe and extends globally, reflecting their participation in large-scale rare disease and biomedical infrastructure programmes.
IOR is one of the few European research hospitals that combines world-class orthopaedic surgery with active participation in translational EU research across regenerative medicine, rare bone diseases, and advanced therapeutics like focused ultrasound. Unlike university labs that stay preclinical, IOR brings real patient cohorts, clinical trial infrastructure, and regulatory experience — essential for any consortium aiming to move from bench to bedside. Their dual strength in both rare musculoskeletal diseases and biomaterial innovation makes them a uniquely valuable clinical validation partner.
